{"pmid":32247821,"title":"3CL(pro) inhibitors as a potential therapeutic option for COVID-19: Available evidence and ongoing clinical trials.","text":["3CL(pro) inhibitors as a potential therapeutic option for COVID-19: Available evidence and ongoing clinical trials.","Pharmacol Res","Sisay, Mekonnen","32247821"],"journal":"Pharmacol Res","authors":["Sisay, Mekonnen"],"date":"2020-04-06T11:00:00Z","year":2020,"_id":"32247821","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.phrs.2020.104779","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663252813971456001,"score":7.622011,"similar":[{"pmid":32213152,"title":"Are there any Therapeutic Options Currently Available for Wuhan Coronavirus?","text":["Are there any Therapeutic Options Currently Available for Wuhan Coronavirus?","Antiinflamm Antiallergy Agents Med Chem","Carradori, Simone","32213152"],"journal":"Antiinflamm Antiallergy Agents Med Chem","authors":["Carradori, Simone"],"date":"2020-03-28T11:00:00Z","year":2020,"_id":"32213152","week":"202013|Mar 23 - Mar 29","doi":"10.2174/1871523019999200228100917","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1662445896479014912,"score":77.46008},{"pmid":32194944,"pmcid":"PMC7062204","title":"Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL (pro)) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates.","text":["Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL (pro)) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates.","We prepared the three-dimensional model of the SARS-CoV-2 (aka 2019-nCoV) 3C-like protease (3CL (pro)) using the crystal structure of the highly similar (96% identity) ortholog from the SARS-CoV. All residues involved in the catalysis, substrate binding and dimerisation are 100% conserved. Comparison of the polyprotein PP1AB sequences showed 86% identity. The 3C-like cleavage sites on the coronaviral polyproteins are highly conserved. Based on the near-identical substrate specificities and high sequence identities, we are of the opinion that some of the previous progress of specific inhibitors development for the SARS-CoV enzyme can be conferred on its SARS-CoV-2 counterpart. With the 3CL (pro) molecular model, we performed virtual screening for purchasable drugs and proposed 16 candidates for consideration. Among these, the antivirals ledipasvir or velpatasvir are particularly attractive as therapeutics to combat the new coronavirus with minimal side effects, commonly fatigue and headache. The drugs Epclusa (velpatasvir/sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) could be very effective owing to their dual inhibitory actions on two viral enzymes.","F1000Res","Chen, Yu Wai","Yiu, Chin-Pang Bennu","Wong, Kwok-Yin","32194944"],"abstract":["We prepared the three-dimensional model of the SARS-CoV-2 (aka 2019-nCoV) 3C-like protease (3CL (pro)) using the crystal structure of the highly similar (96% identity) ortholog from the SARS-CoV. All residues involved in the catalysis, substrate binding and dimerisation are 100% conserved. Comparison of the polyprotein PP1AB sequences showed 86% identity. The 3C-like cleavage sites on the coronaviral polyproteins are highly conserved. Based on the near-identical substrate specificities and high sequence identities, we are of the opinion that some of the previous progress of specific inhibitors development for the SARS-CoV enzyme can be conferred on its SARS-CoV-2 counterpart. With the 3CL (pro) molecular model, we performed virtual screening for purchasable drugs and proposed 16 candidates for consideration. Among these, the antivirals ledipasvir or velpatasvir are particularly attractive as therapeutics to combat the new coronavirus with minimal side effects, commonly fatigue and headache. The drugs Epclusa (velpatasvir/sofosbuvir) and Harvoni (ledipasvir/sofosbuvir) could be very effective owing to their dual inhibitory actions on two viral enzymes."],"journal":"F1000Res","authors":["Chen, Yu Wai","Yiu, Chin-Pang Bennu","Wong, Kwok-Yin"],"date":"2020-03-21T11:00:00Z","year":2020,"_id":"32194944","week":"202012|Mar 16 - Mar 22","doi":"10.12688/f1000research.22457.1","keywords":["*2019-nCoV","*3C-like protease","*COVID-19","*HCV","*Hepatitis C virus","*SARS","*antiviral","*coronavirus","*drug repurpose","*ledipasvir","*molecular modelling","*velpatasvir","*virtual screening"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1662334543180333056,"score":64.436134},{"pmid":32201439,"pmcid":"PMC7074432","title":"Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach.","text":["Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach.","Indian J Pharmacol","Sarma, Phulen","Prajapat, Manisha","Avti, Pramod","Kaur, Hardeep","Kumar, Subodh","Medhi, Bikash","32201439"],"journal":"Indian J Pharmacol","authors":["Sarma, Phulen","Prajapat, Manisha","Avti, Pramod","Kaur, Hardeep","Kumar, Subodh","Medhi, Bikash"],"date":"2020-03-24T11:00:00Z","year":2020,"_id":"32201439","week":"202013|Mar 23 - Mar 29","doi":"10.4103/ijp.IJP_119_20","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1662334543335522305,"score":60.516304},{"pmid":32209887,"title":"Potential therapeutic options for coronavirus disease 2019: using knowledge of past outbreaks to guide future treatment.","text":["Potential therapeutic options for coronavirus disease 2019: using knowledge of past outbreaks to guide future treatment.","Chin Med J (Engl)","Lin, John","Ouyang, Jing","Peng, Xiao-Rong","Isnard, Stephane","Fombuena, Brandon","Routy, Jean-Pierre","Chen, Yao-Kai","32209887"],"journal":"Chin Med J (Engl)","authors":["Lin, John","Ouyang, Jing","Peng, Xiao-Rong","Isnard, Stephane","Fombuena, Brandon","Routy, Jean-Pierre","Chen, Yao-Kai"],"date":"2020-03-27T11:00:00Z","year":2020,"_id":"32209887","week":"202013|Mar 23 - Mar 29","doi":"10.1097/CM9.0000000000000816","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1662444220190818304,"score":47.49299},{"pmid":32173287,"title":"Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines.","text":["Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines.","J Genet Genomics","Liu, Xin","Wang, Xiu-Jie","32173287"],"journal":"J Genet Genomics","authors":["Liu, Xin","Wang, Xiu-Jie"],"date":"2020-03-17T11:00:00Z","year":2020,"_id":"32173287","week":"202012|Mar 16 - Mar 22","doi":"10.1016/j.jgg.2020.02.001","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1662334543635415041,"score":47.04661}]}